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Abstract Northern blot analysis using p40phox cDNA probe
revealed that two sizes of p40phox mRNAs were expressed in
human promyelocytic HL-60 and bone marrow cells. To
characterize these mRNAs, we performed reverse transcription
using total RNA from HL-60 cells, and amplified the coding
region of p40phox by polymerase chain reaction with oligonu-
cleotide primers. Two cDNA fragments with different sizes were
isolated. One was identical to a known p40phox cDNA (1054 bp)
which encoded a protein of 339 residues (39 031 Da) with a
calculated pI of 6.5. The other cDNA (1299 bp) contained an
additional 245 bp intron 8 sequence in the open reading frame
and encoded a protein of 348 residues (39 000 Da) with a
calculated pI of 9.3. N-terminal 253 residues were identical
between p40phox and the variant protein, whereas C-terminal
254^348 residues of the variant protein shared low homology
with p40phox. Interestingly, the variant protein lacked PC (Phox
and Cdc24p) motif of p40phox, which is assumed to be important
for the interaction with p67phox. In addition, Western blot
analysis revealed that the variant protein was not detected in
HL-60 cells and neutrophils. Together, these observations
suggest that alternatively spliced variant mRNA of p40phox is
expressed, but its protein is hardly present in myeloid cells.
z 1999 Federation of European Biochemical Societies.
Key words: NADPH oxidase; p40phox; Cytosolic factor;
Alternative splicing; Neutrophil
1. Introduction
Superoxide-producing NADPH oxidase is a multicompo-
nent system which consists of the membrane-bound cyto-
chrome b558, cytosolic factors (p47phox, p67phox, p40phox
and small GTP-binding proteins Rac1/2) [1]. In resting cells
the enzyme is inactive, and its components are distributed
between the cytosol and membrane. During activation of
NADPH oxidase, cytosolic proteins translocate to the mem-
brane and form the catalytically active complex.
p40phox was originally identi¢ed as the fourth cytosolic
component in guinea pig and human neutrophils by us and
other investigators [2^4]. p40phox is complexed with p67phox
and p47phox in resting cells [2^4], and translocated to the
membrane during activation of NADPH oxidase [3,5,6]. How-
ever, in the cell-free system, NADPH oxidase activation is
fully restored with cytochrome b558, p47phox, p67phox and
rac proteins [7,8], suggesting that p40phox is not an essential
oxidase component. Interestingly, we have suggested that
p40phox may be involved in the activation of NADPH oxi-
dase, because synthetic peptide corresponding to the amino
acid sequence of p40phox inhibits the translocation of cyto-
solic factors and NADPH oxidase activation [5]. Moreover,
Sathyamoorthy et al. have recently revealed using cell-free
reconstitution and whole cell co-transfection techniques that
p40phox is involved in the down-regulation of NADPH oxi-
dase activity [9]. These observations indicate that p40phox has
a role in modulating the activity of NADPH oxidase.
The human p40phox gene is a single copy in chromosomal
location 22q13.1 and spans approximately 18 kb with 10
exons [10]. A 1.2-kb p40phox mRNA is transcribed from
the gene. p40phox mRNA is expressed in myeloid cells such
as neutrophils, eosinophils, basophils, monocytes, and mega-
karyocytes [3,10]. In a preliminary experiment, we have found
by Northern blot analysis that two sizes of p40phox mRNA
transcripts (1.2 and 1.5 kb) are expressed in bone marrow and
promyelocytic leukemia HL-60 cells. Interestingly, for other
NADPH oxidase components rac1 and p47phox, two mRNA
species with di¡erent lengths have been detected by Northern
blot and RNase protection analysis [11^13]. However, these
mRNAs have not been characterized. In this study, we have
identi¢ed the two p40phox mRNAs by the reverse transcrip-
tion-polymerase chain reaction (RT-PCR) technique and
studied the expression of p40phox in neutrophils and HL-60
cells.
2. Materials and methods
2.1. Cell culture and preparation of cells
Human promyelocytic leukemia HL-60 cells were obtained from the
American Type Culture Collection (ATCC CCL-240; Rockville, MD,
USA) [14]. Human monoblastic leukemia U-937 cells were obtained
from the Health Science Research Resource Bank (JCRB9021; Osaka,
Japan) [15]. The cells were maintained in RPMI-1640 medium (Nissui
Pharmaceutical Co. Ltd., Tokyo, Japan) supplemented with 10% fetal
bovine serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin. For
the induction of granulocytic di¡erentiation, HL-60 cells were treated
with 1.3% dimethyl sulfoxide (DMSO) [16]. For the induction of
monocytic di¡erentiation, U-937 cells were treated with 100 ng/ml
phorbol 12-myristate 13-acetate (PMA) [15]. To estimate maturation,
the morphological changes were assessed by staining with May/Gru«n-
wald/Giemsa. The cell growth was assessed by cell-counting. Bone
marrow cells and mature neutrophils were prepared as described pre-
viously [17].
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2.2. Isolation of RNA and Northern blot analysis
Total cellular RNA was isolated from HL-60 and bone marrow
cells by the acid guanidinium thiocyanate-phenol-chloroform extrac-
tion method [18]. Total RNA (2.5 Wg) was separated by electropho-
resis on 1.2% agarose-formaldehyde gel and transferred by capillary
blotting onto nylon membranes (Hybond N, Amersham-Pharmacia
Biotech., Bukinghamshire, UK). RNA was cross-linked with Funa-
UV Linker (Funakoshi Co. Ltd., Tokyo, Japan), and the blots were
hybridized with cDNA probes labeled with DIG high prime DNA
labeling kit (Roche Diagnostics, Mannheim, Germany). Probes used
for Northern blot analysis were the 539-bp p40phox cDNA, 245-bp
p40phox splice variant cDNA (see below), and 2.1-kb (g)-actin cDNA
(pHF(g)A; graciously provided by P. Gunning and L. Kedes, Stan-
ford University) [19].
2.3. cDNA synthesis of p40phox and splice variant
To characterize p40phox mRNAs, we performed RT-PCR using
Titan One Tube RT-PCR kit (Roche Diagnostics). Approximately
1 Wg total RNA was added to a reaction mixture containing
1URT-PCR bu¡er, 1.5 mM MgCl2, 0.2 mM dNTPs, 5 mM DTT,
5 units RNasin, AMV reverse transcriptase, expand PCR enzyme
mixture, and 0.5 WM of each primer. The ¢rst strand cDNA synthesis
was carried out by reverse transcription at 50‡C for 30 min. The
RNA-cDNA hybrid was denatured at 94‡C for 2 min. Then, cDNA
was ampli¢ed for 10 cycles at 94‡C for 30 s; 55‡C for 30 s; 68‡C for
60 s. In the next steps, additional cDNA ampli¢cation was performed
for 30 cycles at 94‡C for 30 s; 55‡C for 30 s; 68‡C for 60 s with 5 s
extension after each cycle. Finally, the elongation step was added at
68‡C for 7 min. Oligonucleotide primers used are as follows: for
ampli¢cation of the coding region of p40phox and splice variant
cDNA, 5P-primer (5P-cggaattcag-ACTCTCCACCTGCTCCCT-3P)
corresponding to nt 1^18 of p40phox and splice variant, and 3P-primer
(5P-gctctagagc-TCATGGCATCGTGTTGTA-3P) corresponding to nt
1037^1054 and nt 1282^1299 of p40phox and splice variant, respec-
tively; for ampli¢cation of 539-bp cDNA probe which recognizes
both p40phox and splice variant, 5P-primer (5P-cggaattcag-AACA-
TTGCTGACATCGAGGA-3P) corresponding to nt 107^126, and
3P-primer (5P-gctctagagc-TGTTGATCCGACTGAGGAGG-3P) corre-
sponding to nt 628^645 of p40phox and splice variant; for ampli¢ca-
tion of p40phox splice variant-speci¢c probe, 5P-primer (5P-cggaatt-
cag-GTCTGTGGCCTGGGAGGGAG-3P) corresponding to nt 793^
812, and 3P-primer (5P-gctctagagc-CTAAGGGGGTGACAGGCT-
GG-3P) corresponding to nt 1018^1037 of the splice variant. The low-
ercase letters represent EcoRI or XbaI recognition sequence included
to facilitate the subcloning of PCR products.
The ampli¢ed cDNA fragments (approximately 1.1 or 1.3 kb) were
puri¢ed with Gene Mate PCRpure SPIN Puri¢cation Kit (Intermoun-
tain Scienti¢c Co. Ltd., UT, USA), digested with EcoRI and XbaI,
and subcloned into a plasmid pBluescript SK(3) (Stratagene, CA,
USA). The sequences of cDNAs were determined by the dideoxy
chain termination method using the Thermosequenase II dye termi-
nator cycle sequencing kit (Amersham-Pharmacia Biotech.) and the
model 373A DNA Sequencer (Applied Biosystems). Both strands of
multiple clones were sequenced using T3 and T7 primers (Promega,
WI, USA), and synthetic oligonucleotide primers based on the cDNA
sequences. Analyses of nucleotide and amino acid sequences were
performed with GENETYX-MAC software (Software Development
Co. Ltd., Tokyo, Japan), and homology search was carried out on the
BLAST program [20].
2.4. In vitro translation of p40phox and splice variant RNA
To perform in vitro translation, pBluescript SK(3) plasmids carry-
ing p40phox and splice variant cDNA were digested with XbaI, and
5 Wg of linear templates were transcribed in vitro with T7 RNA
polymerase (Stratagene) at 37‡C for 90 min. After transcription,
DNA templates were digested with RQ1 RNase-Free DNase (2 units,
Promega) at 37‡C for 15 min. Synthesized RNAs were puri¢ed with
Biospin chromatography column 30 (Bio-Rad Laboratory, CA, USA)
followed by ethanol precipitation. Each RNA (500 ng) was translated
with rabbit reticulocyte lysate (Novagen Inc., WI, USA) at 30‡C for
1 h, and then RNA templates were digested with 10 Wg RNase A at
room temperature for 5 min. Aliquots (5 Wl) of reaction mixtures were
added with 20 Wl sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) sample bu¡er (10% glycerol, 2% SDS, 6.25
Fig. 1. Analysis of the expression of p40phox and splice variant mRNA in human promyelocytic HL-60 and bone marrow cells. Total RNAs
(2.5 Wg) from bone marrow, undi¡erentiated HL-60 and DMSO-treated HL-60 cells were electrophoresed on an agarose-formaldehyde gel and
blotted onto a nylon membrane. The blots were hybridized to digoxigenin-labeled 0.5-kb p40phox cDNA probe corresponding to 107^645 of
p40pox cDNA (A), p40phox splice variant-speci¢c cDNA probe containing 245-bp intron 8 sequence (B) and (g)-actin cDNA probe (C). The
1.2-kb p40phox mRNA (A), the 1.5-kb p40phox splice variant mRNA (A or B) and the 2.2-kb Q-actin mRNA (C) are indicated. D: p40phox
cDNA (nt 1^1054) and splice variant cDNA (nt 1^1299) were ampli¢ed by RT-PCR using undi¡erentiated HL-60 cell RNA. PCR products
were electrophoresed on an agarose gel. The 1.1- and 1.3-kb cDNA fragments are indicated.
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mM Tris-HCl, pH 6.8, 0.02% bromophenol blue, 5% 2-mercapto-
ethanol), and 15 Wl of aliquots were subjected to SDS-PAGE.
2.5. Western blot analysis
HL-60 cells and neutrophils were treated with 5 mM diisopropyl
£uorophosphate (DFP) and disrupted in ice by sonication (Tomy
Ultrasonic Disruptor UD-201, Tominaga Works Ltd). The sonicates
were subjected to SDS-PAGE on 12% polyacrylamide gel and trans-
ferred nitrocellulose membrane (Schleicher and Shuell, Dassel, Ger-
many) [21]. The membrane was blocked in Block Ace (Dainippon
Pharmaceutical Co. Ltd., Osaka, Japan) and probed with a 1:1000
dilution of rabbit anti-p40phox C-terminal peptide-speci¢c anti-
serum [5,22], anti-p40phox N-terminal peptide antiserum or anti-
p40phox splice variant C-terminal peptide-speci¢c antiserum (see be-
low). The membrane was further probed with a 1:2000 dilution of
horseradish peroxidase-conjugated goat anti-rabbit IgG (Organon
Teknika Co., USA), and p40phox proteins were ¢nally detected
with ECL Western blotting detection reagents (Amersharm-Pharma-
cia Biotech.).
Antisera against p40phox N-terminal and p40phox splice variant
C-terminal peptides were raised in rabbits by injection of keyhole
limpet hemocyanin-conjugated synthetic peptides corresponding to
M1AVAQQLRAESDFEQ15 and T336SRWRKISAA345, respectively
[5,22].
Fig. 2. Nucleotide and predicted amino acid sequences of p40phox and splice variant. The nucleotide sequences of p40phox and splice variant
cDNAs are numbered from 5P-ends. The start codons of p40phox and splice variant are located at nt 35. Stop codons (TGA) of p40phox and
splice variant indicated by hyphen (-) are located at nt 1052 and 1118, respectively. The nucleotide sequences of intron 8 inserted into p40phox
mRNA are underlined. The deduced amino acid sequences of p40phox are shown above the nucleotide sequences, and numbered from the
N-terminal methionine. The deduced amino acid sequences of splice variant cDNA are identical to p40phox between Met1 and Lys253, but dif-
ferent from Ser254 to Tyr348, which are shown under the nucleotide sequence of p40phox splice variant. Identical nucleotides are indicated by
asterisks. Nucleotide sequences used for 5P- and 3P-PCR primers are indicated by bold underline. SH3 domain (Ala175-Lys226) and PC motif
(Leu282-Met309) are indicated by open and shaded boxes, respectively. The sequence data in this paper have been submitted to the DDBJ/
EMBL/GenBank DNA database under accession numbers AB025219 and AB025220.
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3. Results and discussion
3.1. Analysis of p40phox mRNA expression
To examine the expression of p40phox mRNA, we per-
formed Northern blot analysis using 0.5-kb p40phox cDNA
probe corresponding to nt 107^645 of p40phox cDNA. Two
sizes (1.2 and 1.5 kb) of p40phox mRNAs were observed in
the bone marrow, undi¡erentiated HL-60 and DMSO-treated
HL-60 cells (Fig. 1A). One was a strong signal (1.2-kb lower
band) with high mobility in the gel, whereas the other was a
slightly weak signal (1.5-kb higher band) with low mobility.
As a control, the expression of (g)-actin mRNA was assessed.
Two sizes of p40phox mRNA transcripts were also detected in
undi¡erentiated and PMA-treated U-937 cells by Northern
blot analysis (data not shown).
3.2. cDNA cloning of p40phox and spliced variant
To characterize these mRNAs, we ampli¢ed p40phox
cDNA fragments using HL-60 cell RNA by RT-PCR techni-
que. Using 5P- and 3P-end primers, two cDNA fragments with
di¡erent sizes (1054 bp and 1299 bp) were obtained (Fig. 1D).
The products were subcloned into a plasmid pBluescript
SK(3) and sequenced. The 1054-bp fragment was identical
to a known p40phox cDNA (EMBL/GenBank/DDBJ acces-
sion number X77094) which encoded a protein of 339 residues
(39 031 Da) with a calculated isoelectric point (pI) of 6.5 (Fig.
2) [3]. The cDNA had two nucleotide substitutions at nt 472^
473 from CA to AC, predicting an amino acid change from
Ala146(GCC)-Ile147(ATC) to Ala146(GCA)-Leu147(CTC). The
other 1299-bp fragment contained an additional 245-bp se-
quence in the open reading frame of p40phox and encoded
a protein of 48 residues (39 000 Da) with a calculated pI of
9.3. As compared with the p40phox genomic DNA sequence
(EMBL/GenBank/DDBJ accession numbers AL008637,
U50727 and U50728), the 245-bp sequence was identical to
the intron 8 sequence [10]. The 1054- and 1299-bp fragments
were also obtained from bone marrow cell RNA by RT-PCR,
and the ampli¢ed cDNA contained the same substitutions
(CA to AC). Northern blot analysis using 245-bp p40phox
splice variant-speci¢c cDNA probe corresponding to 793^
1037 nt (intron 8 sequence) revealed that low mobility bands
represented p40phox splice variant mRNA containing intron
8 sequence (Fig. 1B). These results suggest that p40phox
mRNA is alternatively spliced in myeloid cells. Densitometric
analysis of mRNA bands in Fig. 1A using a scanning densi-
tometer (MasterScan System; Scanalytics, USA) showed the
splice variant mRNA levels in bone marrow, undi¡erentiated
HL-60 and DMSO-treated HL-60 cells were 23%, 88% and
80% of p40phox mRNA levels, respectively. These observa-
tions indicate that the bone marrow cells express the splice
variant mRNA at a relatively low level compared with
p40phox mRNA, whereas HL-60 cells express p40phox and
splice variant mRNAs at almost the same level.
p40phox protein has two motif sequences which are as-
sumed to be important for protein-protein interactions. One
is an src homology 3 (SH3) domain, in which p40phox inter-
acts with the proline-rich region of p47phox [23^25]. The oth-
er is PC (Phox and Cdc24p) motif, in which p40phox interacts
with p67phox [26]. N-terminal 253 residues were identical be-
tween p40phox and the variant protein, and the SH3 domain
was conserved in the variant protein. In contrast, C-terminal
254^348 residues of the variant protein shared low homology
with p40phox, and lacked PC motif.
3.3. Evaluation of the expression of splice variant protein in
myeloid cells
To evaluate the potential translation products of alterna-
tively spliced p40phox mRNA, we ¢rst translated p40phox
and splice variant RNAs in vitro and subjected to Western
blotting (Fig. 3). Both p40phox and splice variant proteins
(approximately 40 kDa) were detected by Western blot anal-
ysis using anti-p40phox N-terminal peptide antibody. In con-
trast, p40phox protein could be detected only by anti-p40phox
C-terminal peptide antibody, but not by p40phox splice var-
iant C-terminal peptide-speci¢c antibody. Moreover, p40phox
splice variant protein could be detected by anti-p40phox splice
variant C-terminal peptide-speci¢c antibody, but not by anti-
p40phox C-terminal peptide antibody. Interestingly, p40phox
was detected in neutrophils by anti-p40phox N-terminal and
C-terminal peptide-speci¢c antibodies, but not detected by
anti-p40phox splice variant-speci¢c antibody. Furthermore,
we evaluated the expression of variant protein in undi¡eren-
tiated and DMSO-treated HL-60 cells by Western blot anal-
ysis. The variant protein was not detected in these cells. Taken
together, these observations suggest that alternatively spliced
variant mRNA of p40phox is expressed, but its protein is
hardly present in myeloid cells. It is not clear at this stage
why p40phox splice variant protein can not be detected in
neutrophils and HL-60 cells. It might be possible that trans-
lation e⁄ciency of p40phox splice variant mRNA is low and/
Fig. 3. Western blot analysis of p40phox and splice variant protein. Peripheral blood neutrophils (1U105 cell equivalents), in vitro translated
p40phox and spliced variant proteins were subjected to 12% SDS-PAGE. Western blotting was performed using anti-p40phox N-terminal pep-
tide antibody (A), anti-p40phox C-terminal peptide-speci¢c antibody (B) and anti-p40phox splice variant C-terminal peptide-speci¢c antibody
(C).
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or cationic p40phox splice variant protein with pI 9.3 is un-
stable in myeloid cells. These possibilities remain to be clari-
¢ed in future.
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